Taken together our results identify AR as a new downstream target of FGF19 in HCC cells, and reveal a functional cross-talk in which the AR/EGFR system could mediate, and likely amplifiy, the tumor-promoting effects of FGF19. Here, AR is linked to hepatocellular carcinoma.